25 of the Best Oncologists Near Me

Veena John, MD, is the System Head for GYN/Medical Oncology for the Northwell Health Cancer Institute and an Assistant Professor of Medicine in the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Board certified in Internal Medicine, Hematology and Medical Oncology, she maintains an active practice caring for patients with gynecologic cancers where she focuses on providing compassionate, personalized, evidence-based multi-disciplinary care. In conjunction with physicians in Surgical Oncology, she pioneered a multi-disciplinary team approach for gynecologic oncology patients at the R.J. Zuckerberg Cancer Center where her practice is based. Dr. John is a highly experienced principal investigator for industry sponsored Phase I, II and III clinical trials in gynecologic oncology. She is the site principal investigator for the NRG cooperative group for the Northwell Health Cancer Institute and co-chair of the protocol review monitoring committee. Dr. John earned her medical degree from Christian Medical College in India, where she also completed her internal medicine internship. She completed her internal medicine residency at Flushing Medical Center and fellowship in hematology and medical oncology at North Shore University Hospital. She is an active member of the Society for Gynecologic Oncology, Society for Immunotherapy in Cancer, American Society of Clinical Oncology and American Society of Hematology as well as a member of the Ovarian Cancer committee for the national Gynecologic Oncology Group. Dr. John is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Testicular Yolk Sac Tumor, and Malignant Mixed Mullerian Tumor. Dr. John is board certified in American Board Of Internal Medicine, American Board Of Internal Medicine/Hematology, and American Board Of Internal Medicine/Medical Oncology.

Dr. Misop Han is David Hall McConnell Professor of Urology and Oncology at the Johns Hopkins School of Medicine. Dr. Han is a urologist whose main clinical focus is in urological oncology with a special emphasis on prostate and kidney cancers. He specializes in robotic nerve-sparing prostatectomy and robotic nephrectomy. Dr. Han received his undergraduate and medical degrees at Johns Hopkins. After an internship in surgery and residency in urology, also at Johns Hopkins, he worked as faculty at Northwestern University and Hospital in Chicago, Illinois. In 2006, he joined the Johns Hopkins faculty. His research interests include the outcome of radical prostatectomy, medical robotics and prediction modeling (what happens to men following surgery for prostate cancer). He has published extensively in these subjects and has received international and national recognition for his research. He is actively involved in several clinical research projects with the database of more than 20,000 men who received surgery for prostate cancer at The Johns Hopkins Hospital. He is a member of the American Urological Association and the American Medical Association. Dr. Han is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Ureterocele, Familial Prostate Cancer, Prostatectomy, and Nephrectomy. Dr. Han is board certified in American Board Of Urology.

Cancer is a terrible disease—often one of the most frightening and uncertain experiences a person can face. My philosophy is to approach every patient with a blend of deep empathy and evidence-based treatment options, empowering them to make informed decisions that align with their values, needs, and goals. I believe that compassionate care and scientific rigor form the foundation of meaningful, personalized cancer care. Dr. Santana is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma. Dr. Santana is board certified in American Board Of Internal Medicine. Dr. Santana is currently accepting new patients.

I specialize in treating people with genitourinary (GU) cancers, such as bladder, prostate, testicular and kidney cancer. I don’t treat other types of cancer across the breadth of tumors like some oncologists in the community may, such as blood cancer, breast cancer or lung cancer. My focus has allowed me to gain deep expertise in GU cancers and to stay abreast of the newest treatment advances, clinical research and so on for those specific GU cancers. As a medical oncologist, I meet patients at one of the scariest moments of their lives. I try to help educate them to make a decision about their disease and its process, and what their treatment options may be, so we can come to a shared decision about what might be the best option. The teaching aspect really strikes home for me. Both of my parents are teachers. The root word for “doctor” in Latin means “to teach.” So that is something I’m both naturally called to do and enjoy doing. Dr. Harrison is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, Chromophobe Renal Cell Carcinoma, and Prostatectomy. Dr. Harrison is board certified in American Board Of Internal Med, Medical Oncology.

Benjamin J. Davies, MD, is a professor of urology at the University of Pittsburgh. He specializes in robotic prostatectomy, robotic cystectomy, and kidney and testicular cancer.Dr. Davies is board-certified in urology. He completed an undergraduate degree at Columbia University in New York and a medical degree at Mount Sinai Medical School in New York. Dr. Davies completed a residency at UPMC, and a fellowship of urologic oncology at University of California, San Francisco.Dr. Davies is a member of professional organizations, such as the American Urologic Association, American Medical Association and the Pittsburgh Urologic Society. He also maintains research interests in prostate cancer epidemiology and surgical outcomes. Dr. Davies is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Cervical Myelopathy, Bladder Cancer, Prostate Cancer, Cystectomy, and Nephrectomy. Dr. Davies is board certified in American Board Of Urology. Dr. Davies is currently accepting new patients.

Sumit Madan is a Hematologist Oncology provider practicing medicine in Gilbert, Arizona. Dr. Madan is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Madan is board certified in American Board Of Internal Medicine/Medical Oncology and American Board Of Internal Medicine/Hematology. Dr. Madan is currently accepting new patients.

Benjamin Teply is an Oncologist practicing medicine in Omaha, Nebraska. He has been practicing medicine for over 16 years. Dr. Teply is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, WT1-Related Wilms Tumor Syndromes, Hormone Replacement Therapy (HRT), and Tissue Biopsy.

Shams Bufalino is a Hematologist and an Oncologist practicing medicine in Park Ridge, Illinois. Dr. Bufalino is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Diffuse Large B-Cell Lymphoma (DLBCL), Large-Cell Immunoblastic Lymphoma, Hodgkin Lymphoma, Classical Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Bufalino is board certified in American Board Of Internal Medicine, Hematology.

Dr. Lin is a medical oncologist specializing in the care of patients with all stages of breast cancer. Her research focuses upon improving the outcomes of people living with metastatic breast cancer, including a particular focus on the challenge of breast cancer brain metastases. She has led multiple clinical trials which have led to new treatment options for patients with breast cancer that has metastasized to the brain. Dr. Lin received her MD from Harvard Medical School in 1999. She completed her residency in internal medicine at Brigham and Women's Hospital and went on to complete fellowships in medical oncology and hematology at Dana-Farber. In 2005, she joined the staff of Brigham and Women's and Dana-Farber, where she is a medical oncologist and clinical investigator in the Breast Oncology Center. Dr. Lin is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Brain Tumor, and Inflammatory Breast Cancer. Dr. Lin is board certified in Medical Oncology.

Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Marilyn Meyerhoff Professor in Thoracic Oncology. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation. Dr. Brahmer is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC). Dr. Brahmer is board certified in American Board Of Internal Medicine.

Mark J. Levis, M.D., Ph.D., professor of oncology, medicine and pharmacology in the Division of Hematologic Malignancies at the Johns Hopkins University School of Medicine, co-directs the Hematologic Malignancies and Bone Marrow Transplantation Program and directs the Adult Leukemia Service at the Johns Hopkins Sidney Kimmel Cancer Center. In addition to his role within the Kimmel Cancer Center, he serves on the faculty for the Johns Hopkins Graduate Training Program in Cellular and Molecular Medicine, a Ph.D. program that prepares scientists to conduct laboratory research at the cellular and molecular level that is designed to have a direct impact on the understanding of human diseases. Dr. Levis has expertise in acute and chronic myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndromes. Dr. Levis received his medical degree at the University of California, San Francisco School of Medicine, where he also earned his Ph.D. in Biochemistry. He completed a residency in internal medicine at Johns Hopkins, followed by fellowships in medical oncology. Dr. Levis is a member of the American Society of Hematology, the American Society of Clinical Oncology and the European Hematology Association. He is an ad hoc member of the Oncology Drug Advisory Committee, as well as an ad hoc manuscript referee for peer-reviewed journals such as New England Journal of Medicine; Leukemia; Clinical Cancer Research; and The American Journal of Hematology. Dr. Levis has earned numerous awards, such as the Daniel Nathans Research Award from Johns Hopkins University, the Osler Housestaff Teaching Award, the Director's Teaching Award in Clinical Science, and the Advanced Clinical Research Award from the American Society of Clinical Oncology. Dr. Levis’ laboratory research focuses on the development of molecularly-targeted therapies for leukemia. He is actively involved in the pre-clinical and clinical development of small molecule inhibitors of protein kinases, including FLT3. The research involves studying the biochemical effects of these inhibitors on samples taken from leukemia patients, with the broad goal of identifying and validating novel molecular therapeutic targets in these hematopoietic malignancies. While Dr. Levis plays a key role in the pre-clinical development of these therapies, he is particularly interested in translating this research to the bedside of his patients by using correlative studies to incorporate these novel therapies into existing treatments. In addition to his work in both the clinic and the laboratory, Dr. Levis has also conducted talks, mentorship and teaching lectures, and published extensively in the top journals in his field, including Leukemia; Blood; and the New England Journal of Medicine. Dr. Levis is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Acute Promyelocytic Leukemia, Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

I am a part of the thoracic oncology program. I work with patients who have cancers of the lung, which includes non-small cell lung cancer, small cell lung cancer, and mesothelioma. My focus is on clinical care, clinical trials, and developing new therapies for these diseases. When I first meet with a patient, I want them to understand what their diagnosis is, because there are actually multiple diagnoses of lung cancer and each are treated differently. Then I discuss with a patient whether they are a candidate for therapies such as molecular therapy or immunotherapy, and make sure they have a clear understanding of the treatment plan. There are some very promising new therapies for these diseases and we are fortunate to have those available to patients here at Duke. That’s one of the unique things we offer as an academic medical center. Dr. Stinchcombe is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery. Dr. Stinchcombe is board certified in American Board Of Internal Med, Medical Oncology.

Daniel Costa is an Internal Medicine specialist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Costa is highly rated in 13 conditions, according to our data. His clinical expertise encompasses EGFR Positive Lung Cancer, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma. Dr. Costa is board certified in American Board Of Internal Medicine.

Jane Meisel is an Oncologist practicing medicine in Atlanta, Georgia. She has been practicing medicine for over 18 years. Dr. Meisel is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, HER-2 Positive Breast Cancer, and Ovarian Cancer. Dr. Meisel is board certified in American Board Of Internal Medicine, 2014.

John Moroney is an Obstetrics and Gynecologist practicing medicine in Orland Park, Illinois. Dr. Moroney is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Ovarian Cancer, Sertoli-Leydig Cell Tumor, Gastrostomy, and Bladder Reconstruction. Dr. Moroney is board certified in Gynecologic Oncology and Practicing Since2002.

Hiten Patel is an Oncologist practicing medicine in Chicago, Illinois. He has been practicing medicine for over 12 years. Dr. Patel is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Prostate Cancer, Testicular Cancer, Nephrectomy, and Prostatectomy. Dr. Patel is board certified in American Board Of Urology - Urology (Certified).

Shira Dinner is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. She has been practicing medicine for over 19 years. Dr. Dinner is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Dinner is board certified in American Board Of Internal Medicine - Hematology (Certified).

I am passionate about offering patients with gynecologic cancer the most cutting-edge surgery and medical therapies. My research and clinical endeavors have focused on the development of novel surgical interventions, robotic surgery and the incorporation of technology to improve cancer outcomes, minimize the recovery from surgery, and decrease complications and side effects. I treat patients with all forms of gynecologic cancers and also offer surgery for complex benign gynecologic conditions. I derive great pleasure from establishing long-term relationships with patients throughout their cancer journey. When not at work, I enjoy cooking, running with my dog, Lucy, and spending time with my husband and sons. Dr. Rossi is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Endometrial Cancer, Cervical Cancer, Neuroendocrine Carcinoma of the Cervix, Lymphadenectomy, and Hysterectomy. Dr. Rossi is board certified in American Board Of Obstetrics/Gynecology, Gynecologic Oncology and American Board Of Obstetrics/Gynecology, Obstetrics & Gynecology.

Ursa Brown is an Oncologist practicing medicine in Santa Fe, New Mexico. Dr. Brown is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, and Cholangiocarcinoma (Bile Duct Cancer). Dr. Brown is board certified in American Board Of Internal Medicine. Dr. Brown is currently accepting new patients.

Glenn Bubley is an Internal Medicine provider practicing medicine in Boston, Massachusetts. Dr. Bubley is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, Prostatectomy, and Orchiectomy. Dr. Bubley is board certified in American Board Of Internal Medicine.

David Einstein is an Internal Medicine specialist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Einstein is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Prostatectomy. Dr. Einstein is board certified in American Board Of Internal Medicine.

Dr. Sekwon Jang is a specialty care physician board certified in internal medicine, hematology, and medical oncology. He has a special interest in management of melanoma and other skin cancers including cutaneous lymphoma. Dr. Jang serves as Director of Melanoma and Cutaneous Oncology Therapeutics and Research and Director of Quality at the Inova Schar Cancer Institute. Before joining Inova, Dr. Jang served as Assistant Professor of Medicine at Georgetown University School of Medicine and Co-Chair of melanoma research group at MedStar Georgetown Cancer Network. Dr. Jang believes in a covenant relationship with his patients, and his goal is to provide the best quality patient-centered care in the setting of multidisciplinary collaboration. Dr. Jang is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Melanoma, Merkel Cell Carcinoma, Cutaneous T-Cell Lymphoma (CTCL), and Squamous Cell Skin Carcinoma.

Shamila Garg is a Hematologist and an Oncologist practicing medicine in Evergreen Park, Illinois. Dr. Garg is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Prostate Cancer. Dr. Garg is board certified in American Board Of Internal Medicine.

Dr. Waqas Jehangir specializes in blood & bone marrow transplant at Avera Medical Group Hematology, Transplant & Cellular Therapy in Sioux Falls, SD. Dr. Jehangir is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Chronic Lymphocytic Leukemia (CLL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Jehangir is board certified in American Board Of Internal Medicine Fellow Of The American College Of Physicians (FACP) Hematology Board Certified Oncology Board Certified Hospice And Palliative Medicine Board Certified.

Seth P. Lerner, MD, is Professor of Urology and holds the Beth and Dave Swalm Chair in Urologic Oncology, in the Scott Department of Urology, Baylor College of Medicine. He is Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program and Faculty Group Practice Medical Director for the Urology Clinic. He earned his medical degree from Baylor College of Medicine, completed a surgical internship at Virginia Mason Hospital in Seattle, and returned to Baylor for his residency training. He completed a two-year fellowship at the University of Southern California in urologic oncology and reconstructive surgery under Peter Jones and Don Skinner before returning to join the full-time Baylor faculty in 1992. His clinical practice, education, and research activities are devoted to urologic oncology and particularly lower and upper tract urothelial cancer. Dr. Lerner is author of more than 160 peer-reviewed articles, and co-editor of a comprehensive Textbook of Bladder Cancer. Dr. Lerner is an active member of the prestigious American Association of Genitourinary surgeons and is listed routinely among America's Top Doctors and Best Doctors in America. He established and directs the multi-disciplinary Bladder Cancer Research Program at Baylor, and his research interests include use of selective estrogen receptor modulators for treatment of bladder cancer, gene therapy, targeted molecular therapeutics, and outcomes of radical cystectomy and pelvic lymphadenectomy. He has 22 years of experience as a clinical investigator for both NCI and industry funded clinical trials. He is the PI of the ongoing SWOG NCI Phase III trial comparing extended vs. standard pelvic lymphadenectomy at time of radical cystectomy for muscle invasive bladder cancer. He is active in the leadership of several national bladder cancer research enterprises including chair of the Local Bladder Cancer committee of SWOG, co-chair of the NCI's Bladder Cancer Task Force and the Analysis Working Group of The Cancer Genome Atlas Project for muscle invasive bladder cancer. He is very active in the Bladder Cancer Advocacy Network (BCAN) as a member of the Board of Directors, past chair of the Bladder Cancer Think Tank and co-chair of the management committee of the Bladder Cancer Research Network. Dr. Lerner is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy. Dr. Lerner is currently accepting new patients.